Corvus Pharmaceuticals (CRVS) Set to Announce Quarterly Earnings on Monday

Corvus Pharmaceuticals (NASDAQ:CRVS) will be releasing its earnings data after the market closes on Monday, May 6th. Analysts expect Corvus Pharmaceuticals to post earnings of ($0.12) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings results on Tuesday, March 19th. The company reported ($0.14) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.14). On average, analysts expect Corvus Pharmaceuticals to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Corvus Pharmaceuticals Stock Up 11.0 %

CRVS opened at $1.92 on Friday. The company has a fifty day simple moving average of $1.80 and a 200 day simple moving average of $1.77. The stock has a market cap of $94.15 million, a P/E ratio of -3.37 and a beta of 1.05. Corvus Pharmaceuticals has a 12 month low of $1.05 and a 12 month high of $4.19.

Analysts Set New Price Targets

CRVS has been the topic of several research analyst reports. Mizuho restated a “neutral” rating and set a $3.50 target price on shares of Corvus Pharmaceuticals in a report on Wednesday, March 27th. Oppenheimer cut their price objective on shares of Corvus Pharmaceuticals from $8.00 to $7.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 20th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Corvus Pharmaceuticals in a report on Monday, April 1st.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.